Sangamo Therapeutics Inc (SGMO)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

7000 MARINA BLVD BRISBANE, CA 94005

Sangamo Therapeutics, Inc. operates as a biotechnology company. The Company focuses on research and development of genomic therapies, as well as develops medicines for patient with genetic diseases. Sangamo Therapeutics serves customers in the United States.

Data as of 2020-08-01
Market Cap1.526 Billion Shares Outstanding140.883 Million Avg 30-day Volume1.932 Million
P/E Ratio Dividend Yield EPS-0.82
Price/Sales16.975 Price cash flow ratio119.2 Price free cash flow ratio-17.1
Book Value2.8 Price to Tangible Book5.26 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.221128
BETA2.26417 52-week High/Low12.38 / 4.81 Stddev0.20716
View SEC Filings from SGMO instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 183 51 (3.34%)
Aggregate 13F shares on 03/31/2020: 73.773 Million 30.86 Million
Aggregate 13F shares on 12/31/2019: 78.143 Million 32.168 Million
Percent change: -5.59% -4.07%
Funds creating new positions: 31 12
Funds Adding to an existing position: 64 20
Funds closing out their position: 31 9
Funds reducing their position: 48 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SGMO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SGMO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WIGGANS THOMAS G

  • Director
0 2020-07-23 0

ZAKRZEWSKI JOSEPH S

0 2020-07-13 4

GREGORY PHILIP D CHIEF SCIENTIFIC OFFICER

36,101 2020-07-02 0

WOLFF HENRY WARD

  • Director
0 2020-07-02 0

RAMASASTRY SAIRA

  • Director
0 2020-06-26 2

MCCLUNG DAVID MARK EVP, CHIEF BUSINESS OFFICER

  • Officer
100,000 2020-06-25 2

NICHOL GEOFFREY

  • Director
0 2020-06-22 0

JEFFS ROGER

  • Director
0 2020-06-19 0

MEYERS JAMES R

  • Director
0 2020-06-17 4

DILLY STEPHEN GEORGE

  • Director
17,905 2020-06-16 4

SMITH KAREN L.

  • Director
54,193 2020-06-11 2

BOISSEL STEPHANE EVP, CORP. STRATEGY

  • Officer
70,116 2020-06-04 5

MENTO STEVEN J

  • Director
82,280 2020-05-22 0

RINGO WILLIAM R

  • Director
0 2020-05-19 0

PARKER H STEWART

  • Director
23,000 2020-05-18 3

CAREY ROBERT

  • Director
15,000 2020-05-18 2

DURAIBABU PRATHYUSHA VP PRINCIPAL ACCT. OFFICER

  • Officer
26,603 2020-04-25 4

CONNER EDWARD R.

  • Director
0 2020-04-22 0

BIOGEN INC.

BIOGEN MA INC.

  • 10% Owner
24,420,157 2020-04-08 1

RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL HEALTHCARE FUND LP

KOLCHINSKY PETER

  • Director
  • 10% Owner
0 2020-04-02 0

MACRAE SANDY PRESIDENT AND CEO

  • Officer
  • Director
247,979 2020-02-25 2

WOOLFSON ADRIAN EVP RESEARCH & DEVELOPMENT

  • Officer
50,000 2020-02-25 1

LOEB GARY EVP, GENERAL COUNSEL & SEC.

  • Officer
50,000 2020-02-25 3

RAMELMEIER ROLF ANDREW EVP, TECHNICAL OPERATIONS

  • Officer
69,128 2020-02-25 2

LEE SUNG EVP, CHIEF FINANCIAL OFFICER

  • Officer
93,750 2020-02-25 3

MARKELS JOHN

  • Director
0 2020-02-11 2

CLEVELAND PAUL B

  • Director
0 2019-10-22 0

YI KATHY EVP & CHIEF FINANCIAL OFFICER

  • Officer
25,512 2019-05-15 0

TURNER HEATHER D EVP, GENERAL COUNSEL & SEC.

  • Officer
19,250 2019-02-25 0

HERBERTS CURT A. III SR.VP & CHIEF BUSINESS OFFICER

  • Officer
14,625 2018-04-13 0

LARSON JOHN WILLIAM

33,180 2017-11-28 0

LANPHIER EDWARD O II

  • Director
1,293,782 2016-12-31 0

ANDO DALE G VP, THERAPEUTIC DEV. & CMO

  • Officer
107,328 2015-12-11 0

ICHIKAWA DAVID G SENIOR VP, BUS. DEV.

  • Officer
25,000 2011-12-08 0

GERBER WILLIAM G

  • Director
0 2010-06-02 0

LIU MARGARET

  • Director
0 2008-06-04 0

WOOD MICHAEL C

  • Director
0 2008-06-04 0

ZANTE GREG VP, FINANCE & ADMINISTRATION

  • Officer
No longer subject to file 2008-03-10 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BOISSEL STEPHANE - Officer EVP, CORP. STRATEGY

2020-07-03 E 1 d 1 0.00 direct

MCCLUNG DAVID MARK - Officer EVP, CHIEF BUSINESS OFFICER

2020-06-25 A 100,000 a 100,000 100,000.00 direct

MCCLUNG DAVID MARK - Officer EVP, CHIEF BUSINESS OFFICER

2020-06-25 A 200,000 a 200,000 100,000.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments